GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eli Lilly and Co (XBUL:LLY) » Definitions » Sale Of Investment

Eli Lilly and Co (XBUL:LLY) Sale Of Investment : лв941 Mil (TTM As of Sep. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Eli Lilly and Co Sale Of Investment?

Eli Lilly and Co's sale of investment for the three months ended in Sep. 2024 was лв190 Mil. It means Eli Lilly and Co gained лв190 Mil from selling investments. Eli Lilly and Co's sale of investment for the trailing twelve months (TTM) ended in Sep. 2024 was лв941 Mil.

Compared with last quarter (лв407 Mil in Jun. 2024 ), Eli Lilly and Co gained less money from selling investments in Sep. 2024 (лв190 Mil).

Eli Lilly and Co Sale Of Investment Historical Data

The historical data trend for Eli Lilly and Co's Sale Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eli Lilly and Co Sale Of Investment Chart

Eli Lilly and Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sale Of Investment
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,421.48 1,688.87 1,613.83 882.90 1,333.69

Eli Lilly and Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Sale Of Investment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 254.05 131.22 213.11 406.79 190.06

Eli Lilly and Co Sale Of Investment Calculation

Sale of Investments represents cash inflow on the sale of investments in securities.

Sale Of Investment for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was лв941 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co Sale Of Investment Related Terms

Thank you for viewing the detailed overview of Eli Lilly and Co's Sale Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.

Eli Lilly and Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eli Lilly and Co (XBUL:LLY) » Definitions » Sale Of Investment
Comparable Companies
JNJ ABBV MRK PFE AMGN GILD BMY BIIB OGN AMRN OCSE:NOVO B XSWX:ROG LSE:AZN XSWX:NOVN XPAR:SAN TSE:4519 LSE:GSK TSE:4568 SHSE:600276 TSE:4578
Traded in Other Exchanges
LLY:USA LLY:Mexico 1LLY:Italy LLY0:Germany LLY:Germany LLY:Germany LLY:Germany LLY:Germany LLYCL:Chile LLY:Switzerland LLY:Canada LILY34:Brazil LLYC:Austria LLY:Argentina
Address
Lilly Corporate Center, Indianapolis, IN, USA, 46285
Website
https://www.lilly.com
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.